Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb:91:107245.
doi: 10.1016/j.intimp.2020.107245. Epub 2020 Dec 1.

Interferon-inducer antivirals: Potential candidates to combat COVID-19

Ashkan Bagheri  1 , Seyed Mohammad Iman Moezzi  1 , Pouria Mosaddeghi  1 , Sadra Nadimi Parashkouhi  1 , Seyed Mostafa Fazel Hoseini  1 , Fatemeh Badakhshan  1 , Manica Negahdaripour  2
Affiliations
Review

Interferon-inducer antivirals: Potential candidates to combat COVID-19

Ashkan Bagheri et al. Int Immunopharmacol. 2021 Feb.

Abstract

Coronavirus disease 2019 (COVID-19) is an infective disease generated by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Given the pandemic urgency and lack of an effective cure for this disease, drug repurposing could open the way for finding a solution. Lots of investigations are ongoing to test the compounds already identified as antivirals. On the other hand, induction of type I interferons are found to play an important role in the generation of immune responses against SARS-CoV-2. Therefore, it was opined that the antivirals capable of triggering the interferons and their signaling pathway, could rationally be beneficial for treating COVID-19. On this basis, using a database of antivirals, called drugvirus, some antiviral agents were derived, followed by searches on their relevance to interferon induction. The examined list included drugs from different categories such as antibiotics, immunosuppressants, anti-cancers, non-steroidal anti-inflammatory drugs (NSAID), calcium channel blocker compounds, and some others. The results as briefed here, could help in finding potential drug candidates for COVID-19 treatment. However, their advantages and risks should be taken into account through precise studies, considering a systemic approach. Even though the adverse effects of some of these drugs may overweight their benefits, considering their mechanisms and structures may give a clue for designing novel drugs in the future. Furthermore, the antiviral effect and IFN-modifying mechanisms possessed by some of these drugs might lead to a synergistic effect against SARS-CoV-2, which deserve to be evaluated in further investigations.

Keywords: Antiviral; COVID-19; Immune system; Interferon; Pandemic; Severe acute respiratory syndrome coronavirus 2.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
The mechanism of action of possible anti-SARS-CoV-2 drugs on the interferon signaling pathway.
See this image and copyright information in PMC

References

    1. De Haan C.A., et al. Mapping of the coronavirus membrane protein domains involved in interaction with the spike protein. J. Virol. 1999;73(9):7441–7452. - PMC - PubMed
    1. Chan J.-F.-W., et al. Interspecies transmission and emergence of novel viruses: lessons from bats and birds. Trends Microbiol. 2013;21(10):544–555. - PMC - PubMed
    1. Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–1242. - PubMed
    1. Lee A.J., Ashkar A.A. The dual nature of type I and type II interferons. Front. Immunol. 2018;9:2061. - PMC - PubMed
    1. Crouse J., Kalinke U., Oxenius A. Regulation of antiviral T cell responses by type I interferons. Nat. Rev. Immunol. 2015;15(4):231–242. - PubMed